These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 31435173)

  • 21. High-dimensional biology to comprehend hepatocellular carcinoma.
    Vivekanandan P; Singh OV
    Expert Rev Proteomics; 2008 Feb; 5(1):45-60. PubMed ID: 18282123
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Application of alpha-fetoprotein and osteopontin combination for early diagnosis of hepatocellular carcinoma associated with hepatitis C.].
    Malov SI; Malov IV; Dvornichenko VV; Rasulov RI; Kuvshinov AG; Marche PN; Decaens T; Macek-Jilkova Z; Yushchuk ND
    Klin Lab Diagn; 2019; 64(10):607-612. PubMed ID: 31742954
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An overview of hepatocellular carcinoma study by omics-based methods.
    Pei Y; Zhang T; Renault V; Zhang X
    Acta Biochim Biophys Sin (Shanghai); 2009 Jan; 41(1):1-15. PubMed ID: 19129945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circulating microRNA's as a diagnostic tool for hepatocellular carcinoma in a hyper endemic HIV setting, KwaZulu-Natal, South Africa: a case control study protocol focusing on viral etiology.
    Sartorius K; Sartorius B; Kramvis A; Singh E; Turchinovich A; Burwinkel B; Madiba T; Winkler CA
    BMC Cancer; 2017 Dec; 17(1):894. PubMed ID: 29282036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of Circulatory RNA-Based Biomarker Panel in Hepatocellular Carcinoma.
    El-Tawdi AH; Matboli M; Shehata HH; Tash F; El-Khazragy N; Azazy Ael-S; Abdel-Rahman O
    Mol Diagn Ther; 2016 Jun; 20(3):265-77. PubMed ID: 27113935
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating predictive and diagnostic biomarkers for hepatitis B virus-associated hepatocellular carcinoma.
    Van Hees S; Michielsen P; Vanwolleghem T
    World J Gastroenterol; 2016 Oct; 22(37):8271-8282. PubMed ID: 27729734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The GALAD scoring algorithm based on AFP, AFP-L3, and DCP significantly improves detection of BCLC early stage hepatocellular carcinoma.
    Best J; Bilgi H; Heider D; Schotten C; Manka P; Bedreli S; Gorray M; Ertle J; van Grunsven LA; Dechêne A
    Z Gastroenterol; 2016 Dec; 54(12):1296-1305. PubMed ID: 27936479
    [No Abstract]   [Full Text] [Related]  

  • 28. Mechanism of exosomal microRNA-224 in development of hepatocellular carcinoma and its diagnostic and prognostic value.
    Cui Y; Xu HF; Liu MY; Xu YJ; He JC; Zhou Y; Cang SD
    World J Gastroenterol; 2019 Apr; 25(15):1890-1898. PubMed ID: 31057302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alpha-Fetoprotein Measurement Benefits Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis.
    Chang TS; Wu YC; Tung SY; Wei KL; Hsieh YY; Huang HC; Chen WM; Shen CH; Lu CH; Wu CS; Tsai YH; Huang YH
    Am J Gastroenterol; 2015 Jun; 110(6):836-44; quiz 845. PubMed ID: 25869392
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum microRNA panels as potential biomarkers for early detection of hepatocellular carcinoma on top of HCV infection.
    Zekri AN; Youssef AS; El-Desouky ED; Ahmed OS; Lotfy MM; Nassar AA; Bahnassey AA
    Tumour Biol; 2016 Sep; 37(9):12273-12286. PubMed ID: 27271989
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma.
    Tremosini S; Forner A; Boix L; Vilana R; Bianchi L; Reig M; Rimola J; Rodríguez-Lope C; Ayuso C; Solé M; Bruix J
    Gut; 2012 Oct; 61(10):1481-7. PubMed ID: 22287594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systematic review of the roles of interleukins in hepatocellular carcinoma.
    Yang H; Xuefeng Y; Jianhua X
    Clin Chim Acta; 2020 Jul; 506():33-43. PubMed ID: 32142718
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating tumor cells: A step toward precision medicine in hepatocellular carcinoma.
    Teng PC; Agopian VG; Lin TY; You S; Zhu Y; Tseng HR; Yang JD
    J Gastroenterol Hepatol; 2022 Jul; 37(7):1179-1190. PubMed ID: 35543075
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aberrant Metabolism in Hepatocellular Carcinoma Provides Diagnostic and Therapeutic Opportunities.
    De Matteis S; Ragusa A; Marisi G; De Domenico S; Casadei Gardini A; Bonafè M; Giudetti AM
    Oxid Med Cell Longev; 2018; 2018():7512159. PubMed ID: 30524660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic value of circulating cell-free DNA levels for hepatocellular carcinoma.
    Yan L; Chen Y; Zhou J; Zhao H; Zhang H; Wang G
    Int J Infect Dis; 2018 Feb; 67():92-97. PubMed ID: 29229500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A structured proteomic approach identifies 14-3-3Sigma as a novel and reliable protein biomarker in panel based differential diagnostics of liver tumors.
    Reis H; Pütter C; Megger DA; Bracht T; Weber F; Hoffmann AC; Bertram S; Wohlschläger J; Hagemann S; Eisenacher M; Scherag A; Schlaak JF; Canbay A; Meyer HE; Sitek B; Baba HA
    Biochim Biophys Acta; 2015 Jun; 1854(6):641-50. PubMed ID: 25448011
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma.
    Chan YT; Zhang C; Wu J; Lu P; Xu L; Yuan H; Feng Y; Chen ZS; Wang N
    Mol Cancer; 2024 Sep; 23(1):189. PubMed ID: 39242496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Newer markers for hepatocellular carcinoma.
    Marrero JA; Lok AS
    Gastroenterology; 2004 Nov; 127(5 Suppl 1):S113-9. PubMed ID: 15508074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biomarker MicroRNAs for Diagnosis, Prognosis and Treatment of Hepatocellular Carcinoma: A Functional Survey and Comparison.
    Shen S; Lin Y; Yuan X; Shen L; Chen J; Chen L; Qin L; Shen B
    Sci Rep; 2016 Dec; 6():38311. PubMed ID: 27917899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glypican-3 is a biomarker and a therapeutic target of hepatocellular carcinoma.
    Wang L; Yao M; Pan LH; Qian Q; Yao DF
    Hepatobiliary Pancreat Dis Int; 2015 Aug; 14(4):361-6. PubMed ID: 26256079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.